Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Redmile Group, LLC and affiliated entities filed Amendment No. 5 to their Schedule 13D on Shattuck Labs, Inc. (STTK), updating their ownership and recent warrant activity. The reporting persons may be deemed to beneficially own 9,819,084 shares of common stock, representing 9.9% of the class.
This includes 7,038,119 shares of common stock held by Redmile funds and, subject to a 9.99% Beneficial Ownership Limitation, 10,943,951 shares issuable upon exercise of Pre-Funded Warrants, of which 2,780,965 shares are counted for beneficial ownership purposes. Redmile funds exercised Common and Pre-Funded Warrants in June 2026, paying about $4.44 million in aggregate exercise price and separately buying additional Pre-Funded Warrants in an underwritten offering for about $3.99 million.
Shattuck Labs director Clay B. Siegall bought 62,500 shares of the company’s common stock in an open-market transaction at $4.00 per share. After this purchase, he directly owns 318,608 shares. The footnote explains the shares were purchased in connection with the company’s underwritten offering that closed on June 11, 2026.
Shattuck Labs, Inc. entered into an underwriting agreement for a public offering of 10,879,376 shares of common stock at $4.00 per share and, in lieu of common stock for certain investors, pre-funded warrants to purchase 7,870,624 shares at $3.9999 per warrant. The company also granted underwriters a 30-day option to buy up to 2,812,500 additional shares, which was exercised in full on June 10, 2026. The securities are being issued under an effective shelf registration statement, with the offering expected to close on June 11, 2026. Pre-funded warrants are immediately exercisable but include beneficial ownership limits between 4.99% and 19.99% depending on holder elections.
Shattuck Labs is offering 10,879,376 shares of common stock and pre-funded warrants to purchase 7,870,624 shares of common stock. The public offering price is $4.00 per share and the exercise price of each pre-funded warrant is $0.0001. Delivery is expected on or about June 11, 2026. Net proceeds to the company are estimated at approximately $70.5M before expenses (or approximately $81.1M if the underwriters’ 30-day option to purchase up to an additional 2,812,500 shares is exercised in full). The offering includes an underwriting syndicate and customary lock-ups; holders of pre-funded warrants will not have stockholder rights until exercise. The prospectus supplement also discloses recent clinical developments for lead candidate SL-325 and that warrant exercises and existing cash support a cash runway into 2029 based on management’s stated assumptions.
Shattuck Labs, Inc. reported that entities affiliated with OrbiMed converted previously issued warrants into new pre-funded warrants and updated their indirect holdings of common stock. On June 8, 2026, OrbiMed-related funds converted common warrants exercisable for 3,073,298 and 15,366,490 shares of common stock into an equal number of pre-funded warrants, with the common warrants carrying an exercise price of $1.0846 per share and the new pre-funded warrants carrying an exercise price of $0.0001 per share. These securities stem from an August 2025 private placement where OrbiMed-affiliated investors purchased 6,306,127 common shares, pre-funded warrants for up to 12,133,661 shares, and accompanying common warrants for up to 18,439,799 shares. All positions are held indirectly through OrbiMed-managed investment funds, and the OrbiMed entities disclaim beneficial ownership beyond any pecuniary interest.
Shattuck Labs director affiliate restructures warrant holdings in STTK. Investment entities associated with OrbiMed converted common warrants into pre-funded warrants linked to Shattuck Labs common stock. Four derivative transactions converted an aggregate of 3,073,298 and 15,366,490 common warrants into corresponding pre-funded warrants at an exercise price of $0.0001 per share.
The common warrants, originally struck at $1.0846 per share, were exchanged on June 8, 2026, leaving no common warrants reported as remaining. The pre-funded warrants are exercisable at any time, subject to a 9.99% beneficial ownership blocker, and will expire once fully exercised. All positions are held indirectly through OrbiMed-managed funds, and the reporting persons and related OrbiMed entities expressly disclaim beneficial ownership beyond any pecuniary interest.
Shattuck Labs, Inc. files a preliminary prospectus supplement to offer shares of common stock and pre-funded warrants in a registered shelf offering, and disclosed recent clinical and financing developments.
The company announced Phase 1 data for lead antibody candidate SL-325 on June 8, 2026, reported notices to exercise approximately $54.9 million of common stock warrants (approximately 50.6M warrants), and stated existing cash, cash equivalents and short-term investments of $90.4 million as of March 31, 2026, with an expected funding runway into 2029 assuming full exercise of remaining warrants.
Shattuck Labs reported encouraging Phase 1 results for SL-325, its lead DR3 blocking antibody, and a major cash influx from warrant exercises. The first-in-human trial in 72 healthy volunteers showed SL-325 was well tolerated across single and multiple ascending doses, with durable DR3 receptor occupancy, no evidence of agonist activity, and a low anti-drug antibody rate of 3.7%.
The company plans to start the RECEPTIVE-CD1 randomized Phase 2b trial of SL-325 in moderate-to-severe Crohn’s disease in the third quarter of 2026 and target 12-week induction data in the first half of 2028. Shattuck also highlighted SL-846, a DR3 x IL-23R bispecific antibody now in IND-enabling toxicology studies, with Phase 1 initiation expected in the first half of 2027.
Financially, Shattuck has received or expects to receive aggregate gross proceeds of approximately $54.9 million from the exercise of about 50.6 million common stock warrants, representing roughly 96% of warrants issued in an August 4, 2025 private placement. Combined with approximately $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, the company now expects to fund operations into 2029 based on current plans.
Shattuck Labs, Inc. reported that director Daniel G. Baker received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036.
The award vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, as long as Baker continues to serve the company. After this grant, he holds options on 81,000 shares directly.
Shattuck Labs, Inc. director George Golumbeski received a compensation-related grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, he holds 81,000 stock options directly.